Why the study?
To evaluate the impact of ertugliflozin on the broader spectrum of all reported heart failure events independent of adjudication confirmation in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Does ertugliflozin reduce investigator-reported heart failure adverse events in participants with type 2 diabetes and atherosclerotic cardiovascular disease?
Population
8238 participants with type 2 diabetes and atherosclerotic cardiovascular disease
Comparison
Pooled ertugliflozin (5 or 15 mg) vs placebo
Design
Post hoc or secondary trial analysis
Follow-up
Mean 3.5 years
Key result
Ertugliflozin reduced the risk of first investigator-reported heart failure adverse events (HR 0.69; 95% CI 0.57-0.84; p < 0.001) in patients with type 2 diabetes and ASCVD.
Authors
Loading...
Supports ertugliflozin for HF risk reduction in T2D with ASCVD; reinforces SGLT2i benefit across investigator-reported and adjudicated endpoints.
RCT (n=8,238)
Does ertugliflozin reduce investigator-reported heart failure adverse events in participants with type 2 diabetes and atherosclerotic cardiovascular disease?
Effect estimate: HR 0.69 (95% CI 0.57-0.84)
p-value: p=<0.001
Ertugliflozin consistently reduces the risk of investigator-reported heart failure adverse events in patients with T2D and ASCVD, with an effect size similar to that seen for adjudicated heart failure hospitalizations.
Pandey et al. (2025) conducted an RCT in Type 2 diabetes and atherosclerotic cardiovascular disease (n=8,238). Ertugliflozin vs. Placebo was evaluated on First investigator-reported heart failure adverse event (HR 0.69, 95% CI 0.57-0.84, p=<0.001). Ertugliflozin reduced the risk of first investigator-reported heart failure adverse events (HR 0.69; 95% CI 0.57-0.84; p < 0.001) in patients with type 2 diabetes and ASCVD.